Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Syncona (SYNC)

Price 116.40p on 29-09-2023 at 16:59:24
Change 10.20p 9.6%
Buy 116.60p
Sell 116.00p
Buy / Sell SYNC Shares
Last Trade: Unknown 5.00 at 116.40p
Day's Volume: 3,548,737
Last Close: 116.40p
Open: 109.00p
ISIN: GG00B8P59C08
Day's Range 106.20p - 117.00p
52wk Range: 105.00p - 205.00p
Market Capitalisation: £782m
VWAP: 113.59612p
Shares in Issue: 672m

Recent Trades History Syncona (SYNC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 5 116.40p Ordinary
Currency Conversion
OTC Trade
16:58:48 - 29-Sep-23
Unknown* 5 116.40p Ordinary
Currency Conversion
OTC Trade
16:55:57 - 29-Sep-23
Unknown* 25,000 116.40p Ordinary
OTC Trade
16:06:49 - 29-Sep-23
Unknown* 1,293 116.406p Ordinary
Currency Conversion
OTC Trade
15:58:28 - 29-Sep-23
Unknown* 5,290 117.00p Ordinary
OTC Trade
15:45:00 - 29-Sep-23
Sell* 100,000 116.40p Ordinary
15:40:39 - 29-Sep-23
Unknown* 402,040 116.268p Ordinary
14:38:25 - 29-Sep-23
Unknown* 402,040 116.168p Ordinary
14:37:53 - 29-Sep-23
Sell* 404,356 116.40p Uncrossing Trade
15:35:20 - 29-Sep-23
Buy* 280 116.60p Automatic Execution
15:29:44 - 29-Sep-23

Share Price History for Syncona

Time period:
Date Open High Low Close Volume

Share News for Syncona

IN BRIEF: Syncona launches GBP40 million share buyback programme

29th Sep 2023 09:51

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation". Read More

Syncona suffers negative valuation hit as Novartis discontinues GT005

11th Sep 2023 09:51

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued. Read More

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

11th Sep 2023 07:54

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data. Read More

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

15th Aug 2023 13:56

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier. Read More

IN BRIEF: Syncona says net asset value slips 1% in first quarter

10th Aug 2023 09:33

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered